Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxford BioMedica is set to take over a manufacturing facility which is established in Oxford, UK from RecipharmCobra Biologics for £1.9m.
Subscribe to our email newsletter
The transaction is expected to get closed by the end of February 2011.
With is acquisition, Oxford BioMedica will have greater control of the production of its proprietary LentiVector gene delivery technology in order to support five of the company’s clinical programmes.
Oxford BioMedica CEO John Dawson said as their ocular programme continues to advance they look forward to the growth of the clinical portfolio from two lead products, ProSavin for Parkinson’s disease and RetinoStat for ‘wet’ AMD, to five clinical products using our proprietary LentiVector gene delivery technology.
"Investment in our specialist manufacturing processes will ensure the rapid progression of these five products through Phase II, Phase III and to market," Dawson said.